Novo Nordisk(US:NVO) Zhi Tong Cai Jing·2026-02-04 02:37Core Viewpoint - Novo Nordisk (NVO.US) reported a strong financial performance for 2025, with total sales reaching 309.1 billion Danish Krone, reflecting a 10% growth at constant exchange rates [1] Group 1: Financial Performance - Total sales for the year amounted to 309.1 billion Danish Krone, with a 10% increase when adjusted for fixed exchange rates [1] - Sales of the entire semaglutide product line reached 228.288 billion Danish Krone [1] - The sales figures for the diabetes treatment semaglutide injection Ozempic (known as 诺和泰 in China) were 127.089 billion Danish Krone, while the weight loss version Wegovy (known as 诺和盈 in China) generated 79.106 billion Danish Krone [1] - The oral formulation of semaglutide (known as 诺和忻 in China) achieved sales of 22.093 billion Danish Krone [1] Group 2: Product Developments - Wegovy tablets, which are administered once daily at a dosage of 25mg, were launched in the U.S. on January 5, with a total weekly prescription volume reaching approximately 50,000 [1] - Novo Nordisk has submitted a supplemental new drug application to the FDA for the 7.2mg version of the weight loss semaglutide injection [1] - The company is also anticipating approval results for next-generation therapies, including Mim8 for hemophilia treatment and CagriSema for obesity treatment [1] Group 3: Market Position - Novo Nordisk holds a leading position in the GLP-1 and insulin markets for diabetes treatment in the Greater China region [1] - The company continues to experience high growth in the obesity and rare disease markets [1]